There is another recently published study, which was financed by Novartis Gene Therapies, which attempted to assess the global prevalence of Rett syndrome via systematic review and meta-analysis. Ten eligible studies were identified (all in females), with a combined sample size of 9.57 million women.
The pooled prevalence estimate (random effects) was 7.1 per 100,000 females (95% CI: 4.8, 10.5, heterogeneity p < 0.001).
With a current female population in the US of 168 million, this suggests a likely US female Rett population of ~ 11,900. Males with Rett syndrome and females aged 35+ were not included in the analysis.
https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-023-02169-6
- Forums
- ASX - By Stock
- NEU
- Ann: Neuren and Acadia expand global partnership for trofinetide
NEU
neuren pharmaceuticals limited
Add to My Watchlist
0.80%
!
$12.54

Ann: Neuren and Acadia expand global partnership for trofinetide, page-128
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$12.54 |
Change
0.100(0.80%) |
Mkt cap ! $1.559B |
Open | High | Low | Value | Volume |
$12.44 | $12.73 | $12.13 | $11.07M | 885.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1215 | $12.52 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$12.54 | 804 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 400 | 12.480 |
1 | 796 | 12.300 |
1 | 400 | 12.240 |
1 | 3000 | 12.230 |
1 | 761 | 12.210 |
Price($) | Vol. | No. |
---|---|---|
12.600 | 1020 | 1 |
12.710 | 628 | 2 |
12.720 | 1982 | 1 |
12.820 | 3050 | 1 |
12.900 | 5012 | 1 |
Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |